Meeting
2020 ASCO Virtual Scientific Program
Phase I/II open label nonrandomized safety and efficacy study of the viral vectored ChAdOx1-MVA 5T4 immunotherapy in combination with PD-1 checkpoint blockade in intermediate-risk localized or locally advanced prostate cancer and advanced metastatic prostate cancer.
Authors
Mark Tuthill
The Jenner Institute, University of Oxford, Oxford, United Kingdom
Mark Tuthill , Federica Cappuccini , Richard John Bryant , Ian Poulton , Emily Pollock , Lucy Carter , Clare Verrill , Armin Meier , Günter Schmidt , James WF Catto , Tom Evans , Silke Gillessen , Andrew Protheroe , Freddie Hamdy , Adrian V.S. Hill , Irina Redchenko
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Vaccines
Clinical Trial Registration Number
NCT03815942
Citation
J Clin Oncol 38: 2020 (suppl; abstr TPS3170)
DOI
10.1200/JCO.2020.38.15_suppl.TPS3170
Abstract #
TPS3170
Poster Bd #
234
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase 1/2 study of the safety, tolerability, and preliminary efficacy of the anti-GITR monoclonal antibody, INCAGN01876, combined with immunotherapies (IO) in patients (Pts) with advanced cancers.
First Author: Martin Gutierrez
Poster
2023 ASCO Genitourinary Cancers Symposium
Phase I results of a phase I/II study of pembrolizumab and AR signaling inhibitor (ARSI) with 225Ac-J591.
First Author: Michael Philip Sun
Poster
2024 ASCO Annual Meeting
High dose bolus (HDB) interleukin-2 (IL2) and concurrent low dose ipilimumab followed sequentially by nivolumab in patients with advanced melanoma after failure of anti-PD1-based immunotherapy and BRAF-MEK inhibition.
First Author: Ahmad A. Tarhini
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Initial findings from the DREAM-GI national database: Assessing the efficacy and safety of neoadjuvant immunotherapy (NIT) in patients with deficient mismatch repair/microsatellite instability-high (dMMR/MSI-H) gastrointestinal (GI) cancer.
First Author: Sakti Chakrabarti